Alastair Greystoke

Academic history

Alastair Greystoke, MBChB, MSc, PhD, MRCP, commenced his medical career with his studies at the University of Manchester, Manchester, UK. After gaining experience through spending 8 years at The Christie NHS Trust, Dr Greystoke went on to joining University of Newcastle and the Northern Centre for Cancer Care as a Honorary Consultant Medical Oncologist in 2014. As a Senior Clinical Lecturer at the same university, he is involved in teaching and mentoring medical students and junior doctors. Additionally, he helps run the Sir Bobby Robson Early Clinical Trials Centre at the Freeman Hospital in Newcastle, and the Pharmacodynamic Biomarker team at the Centre for Cancer Research in Newcastle University.

Speaking on anticancer drug development for lung cancer

With a special commitment to developing new anti-cancer therapeutics for lung cancer, Dr Greystoke co-leads the CONCORDE platform, which integrates new drugs with radical radiotherapy for non-small cell lung cancer (NSCLC). He also serves as the Clinical Lead for Cancer at the Yorkshire, Hull, and North East England Genomic Laboratory Hub. As he possesses a prolific publication record in lung cancer research, Dr Greystoke has contributed extensively to the field, particularly in personalized medicine, circulating biomarkers, and cancer in the elderly.

Currently, Dr Greystoke leads as principal investigator in the PROSPECT-NE genome sequencing project, focusing on advancing personalized medicine for patients over a projected timeline of four years. With his multifaceted expertise, Dr Greystoke continues to pioneer innovative approaches in oncology, driving forward the integration of cutting-edge research into clinical practice for improved patient outcomes.